Sreekumar R found that ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in CRC (Sreekumar et al., 2021). This evidence concerns the gene ZEB2 and colorectal carcinoma.